Indication

Liver transplant rejection

Liver transplant rejection is an immune-mediated complication in which a recipient's immune system identifies the transplanted donor liver as non-self, triggering an inflammatory cascade against the allograft. Read more about Liver transplant rejection

1 drugs 1 manufacturers

Drugs that treat it

Common Liver transplant rejection therapies.

Showing 1–1 of 1 drugs

Sort

ORTHOCLONE OKT3 (muromonab-CD3)

KIDNEY TRANSPLANT REJECTION·+2

CENTOCOR ORTHO

Filter & compare in the drug finder →Opens the drug finder with Liver transplant rejection preselected.

News & literature

Coming soon

Related codes

Coming soon

About Liver transplant rejection.

It primarily impacts allograft recipients and occurs along a spectrum ranging from acute cellular or antibody-mediated rejection—predominantly observed within the first few weeks to months post-transplantation—to late-stage or chronic rejection characterized by vascular obliteration and ductopenia.

Defining clinical and pathophysiologic features include elevated serum aminotransferases and cholestatic liver enzymes, fever, jaundice, abdominal tenderness, and classic histologic findings such as mixed portal triad inflammation, bile duct epithelial injury, and venous endotheliitis.

Left unchecked, severe or refractory rejection can lead to progressive allograft dysfunction and graft loss.

nih.gov
Liver transplant rejection is an immune-mediated complication in which a recipient's immune system identifies the transplanted donor liver as non-self, triggering an inflammatory cascade against the allograft
nih.gov
Liver transplant rejection is an immune-mediated complication in which a recipient's immune system identifies the transplanted donor liver as non-self, triggering an inflammatory cascade against the allograft Defining clinical and pathophysiologic features include elevated serum aminotransferases and cholestatic liver enzymes, fever, jaundice, abdominal tenderness, and classic histologic findings such as mixed portal triad inflammation, bile duct epithelial injury, and venous endotheliitis Left ...
nih.gov
It primarily impacts allograft recipients and occurs along a spectrum ranging from acute cellular or antibody-mediated rejection—predominantly observed within the first few weeks to months post-transplantation—to late-stage or chronic rejection characterized by vascular obliteration and ductopenia
transplantgenomics.com
It primarily impacts allograft recipients and occurs along a spectrum ranging from acute cellular or antibody-mediated rejection—predominantly observed within the first few weeks to months post-transplantation—to late-stage or chronic rejection characterized by vascular obliteration and ductopenia
nih.gov
It primarily impacts allograft recipients and occurs along a spectrum ranging from acute cellular or antibody-mediated rejection—predominantly observed within the first few weeks to months post-transplantation—to late-stage or chronic rejection characterized by vascular obliteration and ductopenia
nih.gov
Defining clinical and pathophysiologic features include elevated serum aminotransferases and cholestatic liver enzymes, fever, jaundice, abdominal tenderness, and classic histologic findings such as mixed portal triad inflammation, bile duct epithelial injury, and venous endotheliitis
aasld.org
Defining clinical and pathophysiologic features include elevated serum aminotransferases and cholestatic liver enzymes, fever, jaundice, abdominal tenderness, and classic histologic findings such as mixed portal triad inflammation, bile duct epithelial injury, and venous endotheliitis
nih.gov
Left unchecked, severe or refractory rejection can lead to progressive allograft dysfunction and graft loss

Personalize your experience

Follow Liver transplant rejection and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it